IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease trial in region

DUBAI: IROS, an Abu Dhabi-based contract research organisation (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever cli…

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease trial in region Read More